Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

5.1K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
5.1K
Drug Discovery: Overview01:26

Drug Discovery: Overview

9.3K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
9.3K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.2K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.2K
Agonism and Antagonism: Quantification01:14

Agonism and Antagonism: Quantification

652
When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
652
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

9.5K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
9.5K
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

6.4K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
6.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial: AI/ML in pharmacovigilance and pharmacoepidemiology.

Frontiers in drug safety and regulation·2025
Same author

Efficient multi-phenotype genome-wide analysis identifies genetic associations for unsupervised deep-learning-derived high-dimensional brain imaging phenotypes.

medRxiv : the preprint server for health sciences·2024
Same author

Prediction of Mild Cognitive Impairment Status: Pilot Study of Machine Learning Models Based on Longitudinal Data From Fitness Trackers.

JMIR formative research·2024
Same author

Montelukast as a repurposable additive drug for standard-efficacy multiple sclerosis treatment: Emulating clinical trials with retrospective administrative health claims data.

Multiple sclerosis (Houndmills, Basingstoke, England)·2024
Same author

Tissue-specific atlas of trans-models for gene regulation elucidates complex regulation patterns.

BMC genomics·2024
Same author

Unsupervised deep representation learning enables phenotype discovery for genetic association studies of brain imaging.

Communications biology·2024

Related Experiment Video

Updated: Oct 6, 2025

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.9K

SynPathy: Predicting Drug Synergy through Drug-Associated Pathways Using Deep Learning.

Yi-Ching Tang, Assaf Gottlieb

    Molecular Cancer Research : MCR
    |January 20, 2022
    PubMed
    Summary

    This study introduces a deep learning method to predict synergistic drug combinations for cancer treatment by analyzing molecular data. It identifies pathway interactions, improving drug discovery and personalized medicine strategies.

    More Related Videos

    High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
    07:51

    High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

    Published on: May 21, 2018

    12.0K
    Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
    03:08

    Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

    Published on: October 3, 2025

    5

    Related Experiment Videos

    Last Updated: Oct 6, 2025

    Diagonal Method to Measure Synergy Among Any Number of Drugs
    12:08

    Diagonal Method to Measure Synergy Among Any Number of Drugs

    Published on: June 21, 2018

    18.9K
    High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
    07:51

    High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

    Published on: May 21, 2018

    12.0K
    Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
    03:08

    Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

    Published on: October 3, 2025

    5

    Area of Science:

    • Computational biology
    • Bioinformatics
    • Machine learning in drug discovery

    Background:

    • Drug combination therapy is a key strategy in cancer treatment.
    • High-throughput screening for synergistic drug combinations is limited by the vast number of potential agents and cell lines.
    • Predicting drug synergy requires understanding complex molecular interactions.

    Purpose of the Study:

    • To develop a biologically-motivated deep learning approach for predicting drug synergy.
    • To identify pathway-level features from molecular data for synergy prediction and interaction quantification.
    • To explore the relationship between pathway proximity and drug synergy.

    Main Methods:

    • Utilized deep learning to analyze drug and cell line molecular data.
    • Identified pathway-level features to predict drug synergy.
    • Quantified interactions in synergistic drug pairs.
    • Analyzed pathway proximity on protein interaction networks.

    Main Results:

    • Achieved a Mean Squared Error (MSE) of 70.6 ± 6.4, outperforming previous methods.
    • Identified potential candidate pathways that explain drug synergy predictions.
    • Demonstrated that drug combinations with closer top contributing pathways on protein interaction networks exhibit higher synergy.

    Conclusions:

    • The deep learning approach effectively predicts drug synergy and quantifies interactions.
    • Pathway proximity on protein interaction networks is a potential indicator for synergistic drug combinations.
    • The computational framework can aid in prescreening and designing novel drug combinations for cancer therapy.